[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |
Advanced search

United States Drugs for Non-small Cell Lung Cancer Market Report 2016

November 2016 | 118 pages | ID: U111D934CDAEN
QYResearch

US$ 3,800.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Notes:

Sales, means the sales volume of Drugs for Non-small Cell Lung Cancer

Revenue, means the sales value of Drugs for Non-small Cell Lung Cancer

This report studies sales (consumption) of Drugs for Non-small Cell Lung Cancer in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering
  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • Menarini
  • Sanofi
  • ZIOPHARM Oncology
  • Alchemia
  • Amgen
  • Apotex
  • BioMarin Pharmaceutical
  • CellAct Pharma
  • Cerulean Pharma
  • Cipla
  • Cornerstone Pharmaceuticals
  • Curis
  • CytRx
  • Eli Lilly
  • Exelixis
  • Fresenius Kabi
  • Genentech
  • Hikma Pharmaceuticals
  • Hospira
  • Intas Pharmaceuticals
  • Karyopharm Therapeutics
  • Kyowa Hakko Kirin
  • Ligand Pharmaceuticals
Split by product types, with sales, revenue, price, market share and growth rate of each type, can be divided into
  • Surgery
  • Radiofrequency ablation (RFA)
  • Radiation therapy
  • Chemotherapy
  • Targeted therapies
  • Immunotherapy
Split by applications, this report focuses on sales, market share and growth rate of Drugs for Non-small Cell Lung Cancer in each application, can be divided into
  • Application 1
  • Application 2
  • Application 3
United States Drugs for Non-small Cell Lung Cancer Market Report 2016

1 DRUGS FOR NON-SMALL CELL LUNG CANCER OVERVIEW

1.1 Product Overview and Scope of Drugs for Non-small Cell Lung Cancer
1.2 Classification of Drugs for Non-small Cell Lung Cancer
  1.2.1 Surgery
  1.2.2 Radiofrequency ablation (RFA)
  1.2.3 Radiation therapy
  1.2.4 Chemotherapy
  1.2.5 Targeted therapies
  1.2.6 Immunotherapy
1.3 Application of Drugs for Non-small Cell Lung Cancer
  1.3.1 Application
  1.3.2 Application
  1.3.3 Application
1.4 United States Market Size Sales (Value) and Revenue (Volume) of Drugs for Non-small Cell Lung Cancer (2011-2021)
  1.4.1 United States Drugs for Non-small Cell Lung Cancer Sales and Growth Rate (2011-2021)
  1.4.2 United States Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate (2011-2021)

2 UNITED STATES DRUGS FOR NON-SMALL CELL LUNG CANCER COMPETITION BY MANUFACTURERS

2.1 United States Drugs for Non-small Cell Lung Cancer Sales and Market Share of Key Manufacturers (2015 and 2016)
2.2 United States Drugs for Non-small Cell Lung Cancer Revenue and Share by Manufactures (2015 and 2016)
2.3 United States Drugs for Non-small Cell Lung Cancer Average Price by Manufactures (2015 and 2016)
2.4 Drugs for Non-small Cell Lung Cancer Market Competitive Situation and Trends
  2.4.1 Drugs for Non-small Cell Lung Cancer Market Concentration Rate
  2.4.2 Drugs for Non-small Cell Lung Cancer Market Share of Top 3 and Top 5 Manufacturers
  2.4.3 Mergers & Acquisitions, Expansion

3 UNITED STATES DRUGS FOR NON-SMALL CELL LUNG CANCER SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (2011-2016)

3.1 United States Drugs for Non-small Cell Lung Cancer Sales and Market Share by Type (2011-2016)
3.2 United States Drugs for Non-small Cell Lung Cancer Revenue and Market Share by Type (2011-2016)
3.3 United States Drugs for Non-small Cell Lung Cancer Price by Type (2011-2016)
3.4 United States Drugs for Non-small Cell Lung Cancer Sales Growth Rate by Type (2011-2016)

4 UNITED STATES DRUGS FOR NON-SMALL CELL LUNG CANCER SALES (VOLUME) BY APPLICATION (2011-2016)

4.1 United States Drugs for Non-small Cell Lung Cancer Sales and Market Share by Application (2011-2016)
4.2 United States Drugs for Non-small Cell Lung Cancer Sales Growth Rate by Application (2011-2016)
4.3 Market Drivers and Opportunities

5 UNITED STATES DRUGS FOR NON-SMALL CELL LUNG CANCER MANUFACTURERS PROFILES/ANALYSIS

5.1 Bristol-Myers Squibb
  5.1.1 Company Basic Information, Manufacturing Base and Competitors
  5.1.2 Drugs for Non-small Cell Lung Cancer Product Type, Application and Specification
    5.1.2.1 Type I
    5.1.2.2 Type II
  5.1.3 Bristol-Myers Squibb Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
  5.1.4 Main Business/Business Overview
5.2 GlaxoSmithKline
  5.2.2 Drugs for Non-small Cell Lung Cancer Product Type, Application and Specification
    5.2.2.1 Type I
    5.2.2.2 Type II
  5.2.3 GlaxoSmithKline Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
  5.2.4 Main Business/Business Overview
5.3 Menarini
  5.3.2 Drugs for Non-small Cell Lung Cancer Product Type, Application and Specification
    5.3.2.1 Type I
    5.3.2.2 Type II
  5.3.3 Menarini Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
  5.3.4 Main Business/Business Overview
5.4 Sanofi
  5.4.2 Drugs for Non-small Cell Lung Cancer Product Type, Application and Specification
    5.4.2.1 Type I
    5.4.2.2 Type II
  5.4.3 Sanofi Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
  5.4.4 Main Business/Business Overview
5.5 ZIOPHARM Oncology
  5.5.2 Drugs for Non-small Cell Lung Cancer Product Type, Application and Specification
    5.5.2.1 Type I
    5.5.2.2 Type II
  5.5.3 ZIOPHARM Oncology Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
  5.5.4 Main Business/Business Overview
5.6 Alchemia
  5.6.2 Drugs for Non-small Cell Lung Cancer Product Type, Application and Specification
    5.6.2.1 Type I
    5.6.2.2 Type II
  5.6.3 Alchemia Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
  5.6.4 Main Business/Business Overview
5.7 Amgen
  5.7.2 Drugs for Non-small Cell Lung Cancer Product Type, Application and Specification
    5.7.2.1 Type I
    5.7.2.2 Type II
  5.7.3 Amgen Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
  5.7.4 Main Business/Business Overview
5.8 Apotex
  5.8.2 Drugs for Non-small Cell Lung Cancer Product Type, Application and Specification
    5.8.2.1 Type I
    5.8.2.2 Type II
  5.8.3 Apotex Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
  5.8.4 Main Business/Business Overview
5.9 BioMarin Pharmaceutical
  5.9.2 Drugs for Non-small Cell Lung Cancer Product Type, Application and Specification
    5.9.2.1 Type I
    5.9.2.2 Type II
  5.9.3 BioMarin Pharmaceutical Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
  5.9.4 Main Business/Business Overview
5.10 CellAct Pharma
  5.10.2 Drugs for Non-small Cell Lung Cancer Product Type, Application and Specification
    5.10.2.1 Type I
    5.10.2.2 Type II
  5.10.3 CellAct Pharma Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
  5.10.4 Main Business/Business Overview
5.11 Cerulean Pharma
5.12 Cipla
5.13 Cornerstone Pharmaceuticals
5.14 Curis
5.15 CytRx
5.16 Eli Lilly
5.17 Exelixis
5.18 Fresenius Kabi
5.19 Genentech
5.20 Hikma Pharmaceuticals
5.21 Hospira
5.22 Intas Pharmaceuticals
5.23 Karyopharm Therapeutics
5.24 Kyowa Hakko Kirin
5.25 Ligand Pharmaceuticals

6 DRUGS FOR NON-SMALL CELL LUNG CANCER MANUFACTURING COST ANALYSIS

6.1 Drugs for Non-small Cell Lung Cancer Key Raw Materials Analysis
  6.1.1 Key Raw Materials
  6.1.2 Price Trend of Key Raw Materials
  6.1.3 Key Suppliers of Raw Materials
  6.1.4 Market Concentration Rate of Raw Materials
6.2 Proportion of Manufacturing Cost Structure
  6.2.1 Raw Materials
  6.2.2 Labor Cost
  6.2.3 Manufacturing Expenses
6.3 Manufacturing Process Analysis of Drugs for Non-small Cell Lung Cancer

7 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

7.1 Drugs for Non-small Cell Lung Cancer Industrial Chain Analysis
7.2 Upstream Raw Materials Sourcing
7.3 Raw Materials Sources of Drugs for Non-small Cell Lung Cancer Major Manufacturers in 2015
7.4 Downstream Buyers

8 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

8.1 Marketing Channel
  8.1.1 Direct Marketing
  8.1.2 Indirect Marketing
  8.1.3 Marketing Channel Development Trend
8.2 Market Positioning
  8.2.1 Pricing Strategy
  8.2.2 Brand Strategy
  8.2.3 Target Client
8.3 Distributors/Traders List

9 MARKET EFFECT FACTORS ANALYSIS

9.1 Technology Progress/Risk
  9.1.1 Substitutes Threat
  9.1.2 Technology Progress in Related Industry
9.2 Consumer Needs/Customer Preference Change
9.3 Economic/Political Environmental Change

10 UNITED STATES DRUGS FOR NON-SMALL CELL LUNG CANCER MARKET FORECAST (2016-2021)

10.1 United States Drugs for Non-small Cell Lung Cancer Sales, Revenue Forecast (2016-2021)
10.2 United States Drugs for Non-small Cell Lung Cancer Sales Forecast by Type (2016-2021)
10.3 United States Drugs for Non-small Cell Lung Cancer Sales Forecast by Application (2016-2021)
10.4 Drugs for Non-small Cell Lung Cancer Price Forecast (2016-2021)

11 RESEARCH FINDINGS AND CONCLUSION

12 APPENDIX

Disclosure Section
Research Methodology
Data Source
Disclaimer

The report requires updating with new data and is sent in 2-3 business days after order is placed.
LIST OF TABLES AND FIGURES

Figure Picture of Drugs for Non-small Cell Lung Cancer
Table Classification of Drugs for Non-small Cell Lung Cancer
Figure United States Sales Market Share of Drugs for Non-small Cell Lung Cancer by Type in 2015
Figure Surgery Picture
Figure Radiofrequency ablation (RFA) Picture
Figure Radiation therapy Picture
Figure Chemotherapy Picture
Figure Targeted therapies Picture
Figure Immunotherapy Picture
Table Application of Drugs for Non-small Cell Lung Cancer
Figure United States Sales Market Share of Drugs for Non-small Cell Lung Cancer by Application in 2015
Figure United States Drugs for Non-small Cell Lung Cancer Sales and Growth Rate (2011-2021)
Figure United States Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate (2011-2021)
Table United States Drugs for Non-small Cell Lung Cancer Sales of Key Manufacturers (2015 and 2016)
Table United States Drugs for Non-small Cell Lung Cancer Sales Share by Manufacturers (2015 and 2016)
Figure 2015 Drugs for Non-small Cell Lung Cancer Sales Share by Manufacturers
Figure 2016 Drugs for Non-small Cell Lung Cancer Sales Share by Manufacturers
Table United States Drugs for Non-small Cell Lung Cancer Revenue by Manufacturers (2015 and 2016)
Table United States Drugs for Non-small Cell Lung Cancer Revenue Share by Manufacturers (2015 and 2016)
Table 2015 United States Drugs for Non-small Cell Lung Cancer Revenue Share by Manufacturers
Table 2016 United States Drugs for Non-small Cell Lung Cancer Revenue Share by Manufacturers
Table United States Market Drugs for Non-small Cell Lung Cancer Average Price of Key Manufacturers (2015 and 2016)
Figure United States Market Drugs for Non-small Cell Lung Cancer Average Price of Key Manufacturers in 2015
Figure Drugs for Non-small Cell Lung Cancer Market Share of Top 3 Manufacturers
Figure Drugs for Non-small Cell Lung Cancer Market Share of Top 5 Manufacturers
Table United States Drugs for Non-small Cell Lung Cancer Sales by Type (2011-2016)
Table United States Drugs for Non-small Cell Lung Cancer Sales Share by Type (2011-2016)
Figure United States Drugs for Non-small Cell Lung Cancer Sales Market Share by Type in 2015
Table United States Drugs for Non-small Cell Lung Cancer Revenue and Market Share by Type (2011-2016)
Table United States Drugs for Non-small Cell Lung Cancer Revenue Share by Type (2011-2016)
Figure Revenue Market Share of Drugs for Non-small Cell Lung Cancer by Type (2011-2016)
Table United States Drugs for Non-small Cell Lung Cancer Price by Type (2011-2016)
Figure United States Drugs for Non-small Cell Lung Cancer Sales Growth Rate by Type (2011-2016)
Table United States Drugs for Non-small Cell Lung Cancer Sales by Application (2011-2016)
Table United States Drugs for Non-small Cell Lung Cancer Sales Market Share by Application (2011-2016)
Figure United States Drugs for Non-small Cell Lung Cancer Sales Market Share by Application in 2015
Table United States Drugs for Non-small Cell Lung Cancer Sales Growth Rate by Application (2011-2016)
Figure United States Drugs for Non-small Cell Lung Cancer Sales Growth Rate by Application (2011-2016)
Table Bristol-Myers Squibb Basic Information List
Table Bristol-Myers Squibb Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Figure Bristol-Myers Squibb Drugs for Non-small Cell Lung Cancer Sales Market Share (2011-2016)
Table GlaxoSmithKline Basic Information List
Table GlaxoSmithKline Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table GlaxoSmithKline Drugs for Non-small Cell Lung Cancer Sales Market Share (2011-2016)
Table Menarini Basic Information List
Table Menarini Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table Menarini Drugs for Non-small Cell Lung Cancer Sales Market Share (2011-2016)
Table Sanofi Basic Information List
Table Sanofi Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table Sanofi Drugs for Non-small Cell Lung Cancer Sales Market Share (2011-2016)
Table ZIOPHARM Oncology Basic Information List
Table ZIOPHARM Oncology Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table ZIOPHARM Oncology Drugs for Non-small Cell Lung Cancer Sales Market Share (2011-2016)
Table Alchemia Basic Information List
Table Alchemia Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table Alchemia Drugs for Non-small Cell Lung Cancer Sales Market Share (2011-2016)
Table Amgen Basic Information List
Table Amgen Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table Amgen Drugs for Non-small Cell Lung Cancer Sales Market Share (2011-2016)
Table Apotex Basic Information List
Table Apotex Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table Apotex Drugs for Non-small Cell Lung Cancer Sales Market Share (2011-2016)
Table BioMarin Pharmaceutical Basic Information List
Table BioMarin Pharmaceutical Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table BioMarin Pharmaceutical Drugs for Non-small Cell Lung Cancer Sales Market Share (2011-2016)
Table CellAct Pharma Basic Information List
Table CellAct Pharma Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table CellAct Pharma Drugs for Non-small Cell Lung Cancer Sales Market Share (2011-2016)
Table Cerulean Pharma Basic Information List
Table Cerulean Pharma Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table Cerulean Pharma Drugs for Non-small Cell Lung Cancer Sales Market Share (2011-2016)
Table Cipla Basic Information List
Table Cipla Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table Cipla Drugs for Non-small Cell Lung Cancer Sales Market Share (2011-2016)
Table Cornerstone Pharmaceuticals Basic Information List
Table Cornerstone Pharmaceuticals Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table Cornerstone Pharmaceuticals Drugs for Non-small Cell Lung Cancer Sales Market Share (2011-2016)
Table Curis Basic Information List
Table Curis Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table Curis Drugs for Non-small Cell Lung Cancer Sales Market Share (2011-2016)
Table CytRx Basic Information List
Table CytRx Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table CytRx Drugs for Non-small Cell Lung Cancer Sales Market Share (2011-2016)
Table Eli Lilly Basic Information List
Table Eli Lilly Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table Eli Lilly Drugs for Non-small Cell Lung Cancer Sales Market Share (2011-2016)
Table Exelixis Basic Information List
Table Exelixis Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table Exelixis Drugs for Non-small Cell Lung Cancer Sales Market Share (2011-2016)
Table Fresenius Kabi Basic Information List
Table Fresenius Kabi Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table Fresenius Kabi Drugs for Non-small Cell Lung Cancer Sales Market Share (2011-2016)
Table Genentech Basic Information List
Table Genentech Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table Genentech Drugs for Non-small Cell Lung Cancer Sales Market Share (2011-2016)
Table Hikma Pharmaceuticals Basic Information List
Table Hikma Pharmaceuticals Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table Hikma Pharmaceuticals Drugs for Non-small Cell Lung Cancer Sales Market Share (2011-2016)
Table Hospira Basic Information List
Table Hospira Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table Hospira Drugs for Non-small Cell Lung Cancer Sales Market Share (2011-2016)
Table Intas Pharmaceuticals Basic Information List
Table Intas Pharmaceuticals Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table Intas Pharmaceuticals Drugs for Non-small Cell Lung Cancer Sales Market Share (2011-2016)
Table Karyopharm Therapeutics Basic Information List
Table Karyopharm Therapeutics Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table Karyopharm Therapeutics Drugs for Non-small Cell Lung Cancer Sales Market Share (2011-2016)
Table Kyowa Hakko Kirin Basic Information List
Table Kyowa Hakko Kirin Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table Kyowa Hakko Kirin Drugs for Non-small Cell Lung Cancer Sales Market Share (2011-2016)
Table Ligand Pharmaceuticals Basic Information List
Table Ligand Pharmaceuticals Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table Ligand Pharmaceuticals Drugs for Non-small Cell Lung Cancer Sales Market Share (2011-2016)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Drugs for Non-small Cell Lung Cancer
Figure Manufacturing Process Analysis of Drugs for Non-small Cell Lung Cancer
Figure Drugs for Non-small Cell Lung Cancer Industrial Chain Analysis
Table Raw Materials Sources of Drugs for Non-small Cell Lung Cancer Major Manufacturers in 2015
Table Major Buyers of Drugs for Non-small Cell Lung Cancer
Table Distributors/Traders List
Figure United States Drugs for Non-small Cell Lung Cancer Production and Growth Rate Forecast (2016-2021)
Figure United States Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate Forecast (2016-2021)
Table United States Drugs for Non-small Cell Lung Cancer Production Forecast by Type (2016-2021)
Table United States Drugs for Non-small Cell Lung Cancer Consumption Forecast by Application (2016-2021 )

More Publications

Need Help?

Ask a Question

Market Reports

All Categories